Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma

BACKGROUND: Pembrolizumab, a PD-1 immune checkpoint inhibitor, is approved as first-line (1L) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) as monotherapy or in combination with platinum and 5-fluorouracil chemotherapy. Limited data exist on the use of these...

Descripción completa

Detalles Bibliográficos
Autores principales: Black, Christopher M., Hanna, Glenn J., Wang, Liya, Ramakrishnan, Karthik, Goto, Daisuke, Turzhitsky, Vladimir, Hair, Gleicy M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241070/
https://www.ncbi.nlm.nih.gov/pubmed/37284189
http://dx.doi.org/10.3389/fonc.2023.1160144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241070/
https://www.ncbi.nlm.nih.gov/pubmed/37284189
http://dx.doi.org/10.3389/fonc.2023.1160144

Ejemplares similares